GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Tax Provision

MGX (Metagenomi) Tax Provision : $-1.73 Mil (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Tax Provision?

Metagenomi's tax provision for the three months ended in Jun. 2024 was $2.20 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2024 was $-1.73 Mil.

Metagenomi Tax Provision Historical Data

The historical data trend for Metagenomi's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Tax Provision Chart

Metagenomi Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
- -2.57 -8.03

Metagenomi Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.90 -1.21 -2.73 - 2.20

Metagenomi Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Tax Provision
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website

Metagenomi Headlines

From GuruFocus

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

By Marketwired • 05-01-2024